- FMOC-L-HYP(BOM)-OH
-
- $0.00 / 1KG
-
2025-04-04
- CAS:187223-15-0
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1Ton
- FMOC-L-HYP(BOM)-OH
-
- $1.00 / 1KG
-
2019-09-02
- CAS:187223-15-0
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1lg; 2kg; 5kg; 10kg; 100kg
|
| | FMOC-L-HYP(BOM)-OH Basic information |
| Product Name: | FMOC-L-HYP(BOM)-OH | | Synonyms: | Fmoc-Hyp(Bcc)-OH;N-alpha-(9-fluorenylmethyloxycarbonyl)-L-Hyp(Boc-aminoethylcarbamoyl);1,2-Pyrrolidinedicarboxylic acid, 4-[[[[2-[[(1,1-diMethylethoxy)carbonyl]aMino]ethyl]aMino]carbonyl]oxy]-, 1-(9H-fluoren-9-ylMethyl) ester, (2S,4R)-;(2S,4R)-4-[[[[2-[[(1,1-Dimethylethoxy)carbonyl]amino]ethyl]amino]carbonyl]oxy]-1,2-pyrrolidinedicarboxylic acid 1-(9H-fluoren-9-ylmethyl) ester;N-ALPHA-(9-FLUORENYLMETHYLOXYCARBONYL)-O-(TERT-BUTYLOXYCARBONYLAMINOETHYLCARBAMOYL)-TRANS-L-HYDROXYPROLINE;FMOC-L-HYP(BOM)-OH;Fmoc-Hyp(Bom)-OH;(9H-Fluoren-9-yl)MethOxy]Carbonyl Hyp(Bom)-OH | | CAS: | 187223-15-0 | | MF: | C28H33N3O8 | | MW: | 539.58 | | EINECS: | 630-406-9 | | Product Categories: | | | Mol File: | 187223-15-0.mol |  |
| | FMOC-L-HYP(BOM)-OH Chemical Properties |
| Boiling point | 749.0±60.0 °C(Predicted) | | density | 1.35±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | form | Solid | | pka | 3.55±0.40(Predicted) | | color | White to pink |
| | FMOC-L-HYP(BOM)-OH Usage And Synthesis |
| Uses | Fmoc-Hyp(Bom)-OH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Hyp(Bom)-OH is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs< | | Synthesis | Step III: Preparation of Fmoc-(2S,4R)-(4-O-CO-NH-CH2-CH2-NH-Boc)-Pro-OH. the methyl ester obtained in step II was converted to free acid by hydrolysis reaction. This is done by adding 1N sodium hydroxide solution to a mixed solvent of 1,4-dioxane and water for the reaction. This step produced a mixture of H-(2S,4R)-(4-O-CO-NH-CH2-CH2-NH-Boc)-Pro-OH with the target product Fmoc-(2S,4R)-(4-O-CO-NH-CH2-CH2-NH-Boc)-Pro-OH. The reaction yield was 55%. | | IC 50 | Cleavable Linker | | References | [1] Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337. DOI:10.1038/nrd.2016.268
[2] Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985. DOI:10.7554/eLife.57277 |
| | FMOC-L-HYP(BOM)-OH Preparation Products And Raw materials |
|